PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION Russian patent published in 2012 - IPC A61K9/10 A61K31/416 A61K47/32 A61J3/00 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical field and deals with drug form for peroral introduction, containing solid dispersion of tyrosine kinase inhibitor, which represents N-[4-(3-amino-1H-indasol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea (ABT869), at least, one pharmaceutically acceptable polymer and pharmaceutically acceptable solubiliser or combination of two or more pharmaceutically acceptable solubilisers, selected from pharmaceutically acceptable non-ionic surgace-active substances, where pharmaceutically acceptable solubiliser has value HLB in the range from 3.5 to 13 and where combination of pharmaceutically acceptable solubilisers has the average HLB value in the range from 4.5 to 12. Invention also relates method of obtaining said drug form.

EFFECT: invention ensures creation of safe drug form, characterised by low level of products of active substance destruction.

11 cl, 3 tbl, 4 ex